JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy

被引：19
|
作者：
Gangat, Naseema [1 ]
Szuber, Natasha [2 ]
Alkhateeb, Hassan [1 ]
Al-Kali, Aref [1 ]
Pardanani, Animesh [1 ]
Tefferi, Ayalew [1 ]
机构：
[1] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN 85259 USA
[2] Univ Montreal, Dept Hematol, Montreal, PQ, Canada
来源：
BLOOD | 2021年 / 138卷 / 26期
关键词：
MECHANISM;
D O I：
10.1182/blood.2021013996
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2886 / 2889
页数：4
相关论文
共 50 条
  • [1] Sodium-glucose cotransporter-2 inhibitor-associated erythrocytosis: A retrospective cohort study
    Liu, Jessica
    Chin-Yee, Benjamin
    Chin-Yee, Ian H.
    Ho, Jenny
    Sadikovic, Bekim
    Hsia, Cyrus C.
    JOURNAL OF INTERNAL MEDICINE, 2024, 295 (01) : 103 - 105
  • [2] Sodium-glucose co-transporter-2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases
    Gangat, Naseema
    Abdallah, Mostafa
    Szuber, Natasha
    Saliba, Antoine
    Alkhateeb, Hassan
    Al-Kali, Aref
    Begna, Kebede H.
    Pardanani, Animesh
    Tefferi, Ayalew
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (07) : E165 - E167
  • [3] Erythrocytosis induced by sodium-glucose cotransporter-2 inhibitors
    Chin-Yee, Benjamin
    Solh, Ziad
    Hsia, Cyrus
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2020, 192 (42) : E1271 - E1271
  • [4] Increased risk of erythrocytosis in men with type 2 diabetes treated with combined sodium-glucose cotransporter-2 inhibitor and testosterone replacement therapy
    Gosmanov, A. R.
    Gemoets, D. E.
    Schumacher, K. A.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2024, 47 (10) : 2615 - 2621
  • [5] Empagliflozin: A sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes
    Dixit, Divisha
    Yoon, Youngmin
    Volino, Lucio R.
    Mansukhani, Rupal Patel
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (22) : 1943 - 1954
  • [6] Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes
    Hedrington, Maka S.
    Davis, Stephen N.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2015, 11 (04) : 613 - 623
  • [7] Risk of erythrocytosis associated with combined use of sodium-glucose cotransporter-2 inhibitors and testosterone replacement therapy in persons with type 2 diabetes
    Schumacher, K.
    Gemoets, D. E.
    Gosmanov, A. R.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2023, 365 : S349 - S349
  • [8] Sodium-glucose cotransporter-2 inhibitor-associated thrombocytopenia
    Bando, Hironori
    Hirota, Yushi
    Ogawa, Wataru
    HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2025, 24 (01): : 165 - 166
  • [9] Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus
    Lamos, Elizabeth M.
    Younk, Lisa M.
    Davis, Stephen N.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2013, 9 (06) : 763 - 775
  • [10] Dapagliflozin: A new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes
    Vivian, Eva M.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (05) : 361 - 372
12345